CA2930866C - Derives d'imidazotriazine a titre de modulateurs de l'activite du tnf - Google Patents

Derives d'imidazotriazine a titre de modulateurs de l'activite du tnf Download PDF

Info

Publication number
CA2930866C
CA2930866C CA2930866A CA2930866A CA2930866C CA 2930866 C CA2930866 C CA 2930866C CA 2930866 A CA2930866 A CA 2930866A CA 2930866 A CA2930866 A CA 2930866A CA 2930866 C CA2930866 C CA 2930866C
Authority
CA
Canada
Prior art keywords
alkyl
methyl
optionally substituted
carboxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2930866A
Other languages
English (en)
Other versions
CA2930866A1 (fr
Inventor
Daniel Christopher Brookings
Julien Alistair Brown
Victoria Elizabeth JACKSON
John Robert Porter
Joanna Rachel Quincey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CA2930866A1 publication Critical patent/CA2930866A1/fr
Application granted granted Critical
Publication of CA2930866C publication Critical patent/CA2930866C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une série de dérivés d'imidazo[1,2-b][1,2,4]triazine substitués de formule (I), qui sont de puissants modulateurs de l'activité du TNFa humain, et sont par conséquent avantageux dans le traitement et/ou la prévention de diverses maladies humaines, comprenant les troubles auto-immuns et inflammatoires; les troubles neurologiques et neurodégénératifs; la douleur et les troubles nociceptifs; les troubles cardiovasculaires; les troubles métaboliques; les troubles oculaires; et les troubles oncologiques.
CA2930866A 2013-12-09 2014-12-08 Derives d'imidazotriazine a titre de modulateurs de l'activite du tnf Active CA2930866C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1321732.8A GB201321732D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
GB1321732.8 2013-12-09
PCT/EP2014/076841 WO2015086503A1 (fr) 2013-12-09 2014-12-08 Dérivés d'imidazotriazine à titre de modulateurs de l'activité du tnf

Publications (2)

Publication Number Publication Date
CA2930866A1 CA2930866A1 (fr) 2015-06-18
CA2930866C true CA2930866C (fr) 2021-10-12

Family

ID=50000415

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930866A Active CA2930866C (fr) 2013-12-09 2014-12-08 Derives d'imidazotriazine a titre de modulateurs de l'activite du tnf

Country Status (10)

Country Link
US (1) US9714251B2 (fr)
EP (1) EP3080129B1 (fr)
JP (1) JP6453332B2 (fr)
CN (1) CN105814060B (fr)
BR (1) BR112016011483A2 (fr)
CA (1) CA2930866C (fr)
ES (1) ES2809530T3 (fr)
GB (1) GB201321732D0 (fr)
RU (1) RU2677699C1 (fr)
WO (1) WO2015086503A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CN115298177A (zh) 2019-10-11 2022-11-04 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (fr) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Derive d'immidazotriazine
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
US6936608B2 (en) * 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2007015866A2 (fr) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires
PL2099447T3 (pl) * 2006-11-22 2013-06-28 Incyte Holdings Corp Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz
PE20090596A1 (es) * 2007-08-14 2009-06-07 Bayer Schering Pharma Ag Imidazoles biciclicos fusionados
WO2009029625A1 (fr) * 2007-08-27 2009-03-05 Kalypsys, Inc. 4-[hétérocyclylméthyl]-8-fluoro-quinolin-2-ones utiles comme inhibiteurs de l'oxyde nitrique synthase
WO2011011712A1 (fr) * 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Imidasotriazines substituées
BR112012003262A8 (pt) * 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CN102812027B (zh) * 2010-02-03 2015-01-07 因西特公司 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014009295A1 (fr) 2012-07-13 2014-01-16 Ucb Pharma S.A. Dérivés d'imidazopyridine utilisables en tant que modulateurs de l'activité tnf

Also Published As

Publication number Publication date
US9714251B2 (en) 2017-07-25
JP2016539974A (ja) 2016-12-22
CA2930866A1 (fr) 2015-06-18
ES2809530T3 (es) 2021-03-04
GB201321732D0 (en) 2014-01-22
RU2016126968A (ru) 2018-01-23
US20160376276A1 (en) 2016-12-29
RU2677699C1 (ru) 2019-01-21
CN105814060B (zh) 2018-02-13
WO2015086503A1 (fr) 2015-06-18
EP3080129B1 (fr) 2020-06-03
BR112016011483A2 (pt) 2017-08-08
JP6453332B2 (ja) 2019-01-16
CN105814060A (zh) 2016-07-27
EP3080129A1 (fr) 2016-10-19

Similar Documents

Publication Publication Date Title
CA2930866C (fr) Derives d'imidazotriazine a titre de modulateurs de l'activite du tnf
CA2931019C (fr) Derives d'imidazopyrimidine a titre de modulateurs de l'activite du tnf
CA2930754C (fr) Derives de pyrazolopyridine comme modulateurs de l'activite du tnf
CA2930209C (fr) Derives de tetrahydroimidazopyridine substitues comme modulateurs de l'activite du tnf
CA2931583C (fr) Derives d'imidazopyridine comme modulateurs de l'activite du tnf
CA2930499C (fr) Derives d'imidazopyridine comme modulateurs de l'activite du tnf
CA2931584C (fr) Derives de benzotriazole comme modulateurs de l'activite du tnf
CA2931026C (fr) Derives d'imidazopyridazine a titre de modulateurs de l'activite du tnf
CA2931586C (fr) Derives d'imidazopyridine comme modulateurs de l'activite du tnf
CA2931581C (fr) Derives de purine a titre de modulateurs de l'activite du tnf
CA2930142C (fr) Derives de tetrahydrobenzimidazole substitues comme modulateurs de l'activite du tnf-a
CA2931578C (fr) Derives de triazolopyridine comme modulateurs de l'activite du tnf
WO2015086523A1 (fr) Dérivés hétéroaromatiques bicycliques condensés comme modulateurs de l'activité du tnf
CA2931022C (fr) Derives d'imidazopyridine comme modulateurs de l'activite du tnf
CA2930912C (fr) Derives d'heteroaryl-imidazole a 5 membres fusionnes comme modulateurs de l'activite tnf
CA2930757C (fr) Derives de tetrahydroimidazopyridine comme modulateurs de l'activite du tnf
CA2930345C (fr) Derives de triazolopyridazine a titre de modulateurs de l'activite du tnf

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191120